These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
608 related articles for article (PubMed ID: 21415776)
1. Phase II study of pemetrexed and cisplatin, with chest radiotherapy followed by docetaxel in patients with stage III non-small cell lung cancer. Gadgeel SM; Ruckdeschel JC; Patel BB; Wozniak A; Konski A; Valdivieso M; Hackstock D; Chen W; Belzer K; Burger AM; Marquette L; Turrisi A J Thorac Oncol; 2011 May; 6(5):927-33. PubMed ID: 21415776 [TBL] [Abstract][Full Text] [Related]
2. Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: satellite--a phase II study from the Swedish Lung Cancer Study Group. Hallqvist A; Wagenius G; Rylander H; Brodin O; Holmberg E; Lödén B; Ewers SB; Bergström S; Wichardt-Johansson G; Nilsson K; Ekberg L; Sederholm C; Nyman J Lung Cancer; 2011 Feb; 71(2):166-72. PubMed ID: 20541833 [TBL] [Abstract][Full Text] [Related]
3. Phase I study of concurrent chemoradiation with pemetrexed and cisplatin followed by consolidation pemetrexed for patients with unresectable stage III non-small cell lung cancer. Cardenal F; Arnaiz MD; Morán T; Jové J; Nadal E; Porta R; Solé JM; Brao I; Palmero R; Fuentes R; Núñez I; Caveda E; Cassinello A Lung Cancer; 2011 Oct; 74(1):69-74. PubMed ID: 21353323 [TBL] [Abstract][Full Text] [Related]
4. Oral vinorelbine and cisplatin with concurrent radiotherapy after induction chemotherapy with cisplatin and docetaxel for patients with locally advanced non-small cell lung cancer: the GFPC 05-03 study. Descourt R; Vergnenegre A; Barlesi F; Lena H; Fournel P; Falchero L; Berard H; Hureaux J; Le Caer H; Chavaillon JM; Geriniere L; Monnet I; Chouabe S; Robinet G; J Thorac Oncol; 2011 Feb; 6(2):351-7. PubMed ID: 21164367 [TBL] [Abstract][Full Text] [Related]
5. Final results from a Phase II study of pemetrexed and cisplatin with concurrent thoracic radiation after Pem-Cis induction in patients with unresectable locally advanced non-squamous non-small cell lung cancer (NSCLC). Garrido P; Engel-Riedel W; Serke M; Giraud P; Ricardi U; Vallejo C; Visseren-Grul C; Ameryckx S; Soldatenkova V; Chouaki N; Novello S Lung Cancer; 2015 May; 88(2):160-6. PubMed ID: 25758556 [TBL] [Abstract][Full Text] [Related]
6. Full-dose pemetrexed plus cisplatin combined with concurrent thoracic radiotherapy for previously untreated advanced nonsquamous non-small cell lung cancer. Zhang Q; Cai XW; Zhu ZF; Yu W; Liu Q; Feng W; Xue MC; Fu XL Anticancer Drugs; 2015 Apr; 26(4):456-63. PubMed ID: 25646743 [TBL] [Abstract][Full Text] [Related]
7. A phase II study of concurrent chemoradiation with weekly docetaxel, carboplatin, and radiation therapy followed by consolidation chemotherapy with docetaxel and carboplatin for locally advanced inoperable non-small cell lung cancer (NSCLC). Jain AK; Hughes RS; Sandler AB; Dowlati A; Schwartzberg LS; Dobbs T; Schlabach L; Wu J; Muldowney NJ; Choy H J Thorac Oncol; 2009 Jun; 4(6):722-7. PubMed ID: 19404213 [TBL] [Abstract][Full Text] [Related]
8. Irinotecan and cisplatin with concurrent split-course radiotherapy in locally advanced nonsmall-cell lung cancer: a multiinstitutional phase 2 study. Fukuda M; Soda H; Fukuda M; Kinoshita A; Nakamura Y; Nagashima S; Takatani H; Tsukamoto K; Kohno S; Oka M Cancer; 2007 Aug; 110(3):606-13. PubMed ID: 17577234 [TBL] [Abstract][Full Text] [Related]
9. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744 [TBL] [Abstract][Full Text] [Related]
10. Thymidylate synthase expression and outcome of patients receiving pemetrexed for advanced nonsquamous non-small-cell lung cancer in a prospective blinded assessment phase II clinical trial. Nicolson MC; Fennell DA; Ferry D; O'Byrne K; Shah R; Potter V; Skailes G; Upadhyay S; Taylor P; André V; Nguyen TS; Myrand SP; Visseren-Grul C; Das M; Kerr KM J Thorac Oncol; 2013 Jul; 8(7):930-9. PubMed ID: 23722170 [TBL] [Abstract][Full Text] [Related]
11. Phase II study of perioperative chemotherapy with cisplatin and pemetrexed in non-small-cell lung cancer. Dy GK; Bogner PN; Tan W; Demmy TL; Farooq A; Chen H; Yendamuri SS; Nwogu CE; Bushunow PW; Gannon J; Adjei AA; Adjei AA; Ramnath N J Thorac Oncol; 2014 Feb; 9(2):222-30. PubMed ID: 24419420 [TBL] [Abstract][Full Text] [Related]
12. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer. Smit EF; Burgers SA; Biesma B; Smit HJ; Eppinga P; Dingemans AM; Joerger M; Schellens JH; Vincent A; van Zandwijk N; Groen HJ J Clin Oncol; 2009 Apr; 27(12):2038-45. PubMed ID: 19307503 [TBL] [Abstract][Full Text] [Related]
13. Docetaxel consolidation therapy following cisplatin, vinorelbine, and concurrent thoracic radiotherapy in patients with unresectable stage III non-small cell lung cancer. Sekine I; Nokihara H; Sumi M; Saijo N; Nishiwaki Y; Ishikura S; Mori K; Tsukiyama I; Tamura T J Thorac Oncol; 2006 Oct; 1(8):810-5. PubMed ID: 17409964 [TBL] [Abstract][Full Text] [Related]
14. Three-Year Follow-Up of a Randomized Phase II Trial on Refinement of Early-Stage NSCLC Adjuvant Chemotherapy with Cisplatin and Pemetrexed versus Cisplatin and Vinorelbine (the TREAT Study). Kreuter M; Vansteenkiste J; Fischer JR; Eberhardt WE; Zabeck H; Kollmeier J; Serke M; Frickhofen N; Reck M; Engel-Riedel W; Neumann S; Thomeer M; Schumann C; De Leyn P; Graeter T; Stamatis G; Griesinger F; Thomas M; J Thorac Oncol; 2016 Jan; 11(1):85-93. PubMed ID: 26762743 [TBL] [Abstract][Full Text] [Related]
15. Phase I study of pemetrexed and cisplatin with concurrent high-dose thoracic radiation after induction chemotherapy in patients with unresectable locally advanced non-small cell lung cancer. Mornex F; Peignaux K; Germain T; Wautot V; Chouaki N; Bourayou N; Tourani JM Lung Cancer; 2013 Apr; 80(1):68-74. PubMed ID: 23332163 [TBL] [Abstract][Full Text] [Related]
16. Docetaxel and exisulind in previously treated non-small cell lung cancer (NSCLC) patients: a multicenter, phase II clinical trial. Weiss GJ; Vokes EE; Bunn PA; Magree L; Rusk J; Albert D; Kelly K J Thorac Oncol; 2007 Oct; 2(10):933-8. PubMed ID: 17909356 [TBL] [Abstract][Full Text] [Related]
17. A randomized phase 3 trial comparing pemetrexed/carboplatin and docetaxel/carboplatin as first-line treatment for advanced, nonsquamous non-small cell lung cancer. Rodrigues-Pereira J; Kim JH; Magallanes M; Lee DH; Wang J; Ganju V; Martínez-Barrera L; Barraclough H; van Kooten M; Orlando M J Thorac Oncol; 2011 Nov; 6(11):1907-14. PubMed ID: 22005471 [TBL] [Abstract][Full Text] [Related]
18. Concomitant chemoradiotherapy using pemetrexed and carboplatin for unresectable stage III non-small cell lung cancer (NSCLC): preliminary results of a phase II study. Xu Y; Ma S; Ji Y; Sun X; Jiang H; Chen J; Du X; Zheng Y; Qiu G Lung Cancer; 2011 Jun; 72(3):327-32. PubMed ID: 21056507 [TBL] [Abstract][Full Text] [Related]
19. Phase 2 study of pemetrexed plus carboplatin, or pemetrexed plus cisplatin with concurrent radiation therapy followed by pemetrexed consolidation in patients with favorable-prognosis inoperable stage IIIA/B non-small-cell lung cancer. Choy H; Schwartzberg LS; Dakhil SR; Garon EB; Gerber DE; Choksi JK; Govindan R; Peng G; Koustenis A; Treat J; Obasaju C J Thorac Oncol; 2013 Oct; 8(10):1308-16. PubMed ID: 23981966 [TBL] [Abstract][Full Text] [Related]
20. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. Hanna N; Neubauer M; Yiannoutsos C; McGarry R; Arseneau J; Ansari R; Reynolds C; Govindan R; Melnyk A; Fisher W; Richards D; Bruetman D; Anderson T; Chowhan N; Nattam S; Mantravadi P; Johnson C; Breen T; White A; Einhorn L; ; J Clin Oncol; 2008 Dec; 26(35):5755-60. PubMed ID: 19001323 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]